DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 33 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,198,813 | -29.3% | 1,646,195 | -31.2% | 0.00% | -33.3% |
| Q2 2023 | $28,566,725 | -6.4% | 2,392,523 | +4.8% | 0.01% | -14.3% |
| Q1 2023 | $30,528,203 | -19.8% | 2,283,336 | +29.1% | 0.01% | -22.2% |
| Q4 2022 | $38,049,556 | +10.1% | 1,768,102 | +2.5% | 0.01% | +12.5% |
| Q3 2022 | $34,555,000 | +1.9% | 1,725,142 | -8.9% | 0.01% | 0.0% |
| Q2 2022 | $33,912,000 | +10839.4% | 1,894,537 | +5969.9% | 0.01% | – |
| Q1 2022 | $310,000 | -25.1% | 31,212 | +27.2% | 0.00% | – |
| Q4 2021 | $414,000 | +56.8% | 24,546 | +111.7% | 0.00% | – |
| Q2 2021 | $264,000 | – | 11,594 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 2,548,403 | $54,841,633 | 43.06% |
| PATHWAY CAPITAL MANAGEMENT, LP | 995,686 | $21,427,163 | 38.24% |
| Atlas Venture Life Science Advisors, LLC | 7,568,317 | $162,870,182 | 19.62% |
| RA Capital Management | 7,040,622 | $151,514,185 | 3.07% |
| COMMODORE CAPITAL LP | 739,661 | $15,918 | 2.40% |
| GREAT POINT PARTNERS LLC | 544,451 | $11,716,586 | 2.30% |
| Nicholas Investment Partners, LP | 786,554 | $16,926,642 | 1.48% |
| Boxer Capital, LLC | 1,189,943 | $25,607,573 | 1.35% |
| Parkman Healthcare Partners LLC | 224,483 | $4,830,874 | 1.29% |
| Cheyne Capital Management (UK) LLP | 27,223 | $585,839 | 1.02% |